| Autor: |
Amber L. Beitelshees, James M. Stevenson, Nihal El Rouby, Chrisly Dillon, Philip E. Empey, Elliot M. Fielstein, Julie A. Johnson, Nita A. Limdi, Henry H. Ong, Francesco Franchi, Dominick J. Angiolillo, Joshua F. Peterson, Marc B. Rosenman, Todd C. Skaar, Sony Tuteja, Larisa H. Cavallari |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Genetics in medicine : official journal of the American College of Medical Genetics |
| ISSN: |
1098-3600 |
| DOI: |
10.1038/s41436-020-0894-2 |
| Popis: |
Purpose. Genotype-guided antiplatelet therapy is increasingly being incorporated into clinical care. The purpose of this study is to determine the extent to which patients initially genotyped for CYP2C19 to guide antiplatelet therapy were prescribed additional medications affected by CYP2C19. Methods. We assembled a cohort of patients from eight sites performing CYP2C19 genotyping to inform antiplatelet therapy. Medication orders were evaluated from time of genotyping through one year. The primary endpoint was the proportion of patients prescribed two or more CYP2C19 substrates. Secondary endpoints were the proportion of patients with a drug-genotype interaction and time to receiving a CYP2C19 substrate. Results. 9,191 genotyped patients (17% non-white) with a mean age of 68 ± 3 years were evaluated. 4,701 (51%) of patients received two or more CYP2C19 substrates. 3,835 (42%) of patients had a drug-genotype interaction. The average time between genotyping and CYP2C19 substrate other than antiplatelet therapy was 25 ± 10 days. Conclusions. More than half of patients genotyped in the setting of CYP2C19-guided antiplatelet therapy received another medication impacted by CYP2C19 in the following year. Given that genotype is stable for a patient’s lifetime, this finding has implications for cost effectiveness, patient care, and treatment outcomes beyond the indication for which it was originally performed. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink